AOA Dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. AOA Dx was co-founded by three experts and passionate advocates of women’s health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization.